B Cell Marker Inhibitors belong to a distinctive chemical class characterized by their ability to interfere with specific molecular markers found on the surface of B cells. B cells are a crucial component of the immune system, playing a pivotal role in the body's defense against pathogens and the production of antibodies. These inhibitors act by selectively targeting and binding to the identified surface markers, resulting in the inhibition of certain signaling pathways or cellular processes associated with B cell function.
By doing so, B Cell Marker Inhibitors can modulate B cell activity and potentially impact various immune responses. Their unique mechanism of action makes them promising candidates for further research and investigation in immunology and related fields. As a chemical class, these inhibitors offer valuable tools for scientific exploration and have the potential to shed light on the complex interactions within the immune system.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
This inhibitor targets Bruton's tyrosine kinase (BTK), a protein essential for B-cell survival. It is used for various B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Similar to ibrutinib, acalabrutinib targets BTK and is used for mantle cell lymphoma and chronic lymphocytic leukemia. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
This inhibitor targets phosphoinositide 3-kinase (PI3K) delta, a protein involved in B-cell signaling. It is studied in the research of chronic lymphocytic leukemia and follicular lymphoma. | ||||||
IPI 145 | 1201438-56-3 | sc-488318 | 5 mg | $317.00 | ||
Like idelalisib, duvelisib also targets PI3K delta and is studied in the research of chronic lymphocytic leukemia and small lymphocytic lymphoma. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Although primarily a B-cell lymphoma-2 (BCL-2) inhibitor, ABT-199 affects B-cells by promoting cell death (apoptosis). It is studied in the research of chronic lymphocytic leukemia and certain types of lymphomas. | ||||||